Clinical Edge Journal Scan

Chronic lymphocytic leukemia: A risk factor for poor outcomes in patients hospitalized with immune thrombocytopenia


 

Key clinical point: Patients hospitalized with immune thrombocytopenia (ITP) and concomitant chronic lymphocytic leukemia ( CLL) have a greater risk for death, require more blood products, and have poorer hospitalization outcomes compared with those with ITP without CLL.

Major finding : The risks for all-cause mortality (adjusted odds ratio [aOR] 1.28), gastrointestinal bleeding (aOR 1.19), packed red blood cell transfusion (aOR 1.79), splenectomy (aOR 1.30), and platelet transfusion (aOR, 1.49) were higher in patients with ITP and CLL vs those with ITP without CLL (all P < .01).

Study details: The data come from a retrospective study including patients hospitalized for ITP who did (n = 15,672) and did not (n = 646,499) have concurrent CLL.

Disclosures: This study did not report the source of funding. Some authors declared receiving research grants or consulting fees from various sources.

Source: Ammad Ud Din M et al. Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: An analysis of the National Inpatient Sample Database. Ann Hematol. 2023;102(4):889-895 (Feb 13). Doi: 10.1007/s00277-023-05133-5

Recommended Reading

Relapsed follicular lymphoma: Autologous stem cell transplantation shows long-term curative effects
B-Cell Lymphoma ICYMI
Ibrutinib shows long-term benefits in chronic lymphocytic leukemia/small lymphocytic lymphoma in RESONATE-2
B-Cell Lymphoma ICYMI
Diffuse large B-cell lymphoma: No impact of lenalidomide after R-CHOP on unfavorable prognosis of low NK-cell counts
B-Cell Lymphoma ICYMI
Diagnosis to treatment interval: A crucial prognostic factor in newly diagnosed mantle cell lymphoma
B-Cell Lymphoma ICYMI
Commentary: New treatment strategies for diffuse large B-cell lymphoma, March 2023
B-Cell Lymphoma ICYMI
CLL treatment: More infections among real-world patients
B-Cell Lymphoma ICYMI
CLL and surgery are more compatible than ever
B-Cell Lymphoma ICYMI
Brexucabtagene autoleucel shows promise in relapsed or refractory mantle cell lymphoma in routine practice
B-Cell Lymphoma ICYMI
Venetoclax may bridge to immunotherapy in relapsed/refractory mantle cell lymphoma
B-Cell Lymphoma ICYMI
Long-term benefits of axicabtagene ciloleucel in refractory large B-cell lymphoma
B-Cell Lymphoma ICYMI